Clin2
NCT07550296Possibly a fitRecruiting

Second IV Clot-Dissolving Treatment for Major Stroke

Acute Ischemic Stroke

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests giving a second dose of an IV clot-dissolving medicine (prourokinase) to patients who had a stroke from a large clot but didn't improve enough after the first dose. The goal is to see if a second dose within 6 hours of stroke onset can help more patients recover.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
122 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You had a major stroke (large or medium vessel clot) and received IV prourokinase within 4.5 hours of symptom start
  • Your stroke didn't improve much (or got worse) 1 hour after the first treatment, and imaging confirms the clot is still there
  • You have a neurological exam score (NIHSS) of at least 4, and your brain imaging score (ASPECTS) is at least 6
  • You are at least 18 years old and either having your first stroke or a past stroke with no lasting problems
  • You are not scheduled for endovascular thrombectomy (mechanical clot removal) and have no blood clotting disorders

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07787325Not yet recruiting
Clot-busting drug for recent stroke within 4.5 hours

This study tests a clot-dissolving medication given within 4.5 hours of a stroke caused by a blocked blood vessel. The goal is to see how well it works in real-world patients and to help improve recovery.

Hefei, Anhui
NCT07776873Recruiting· Phase 3
Clot-busting medicine for stroke symptoms 4.5 to 24 hours

This study tests a clot-busting medicine given through an IV to people who had a stroke caused by a blocked medium-sized blood vessel in the brain, and who can be treated 4.5 to 24 hours after symptoms start. The goal is to see if it improves recovery and reduces disability compared to standard care.

Hefei, Anhui
NCT07617870Not yet recruiting· Phase 3
Clot-busting treatment for late-window posterior stroke

This study tests whether a clot-busting drug called pro-urokinase can help people with a stroke in the back of the brain when given later than usual (4.5 to 9 hours after symptoms start). The goal is to see if it improves recovery and reduces disability.

Zhengzhou, Henan
NCT06801054Not yet recruiting· Phase 1
Second clot-dissolving dose for stroke that doesn't improve

This trial studies whether giving a second dose of a clot-busting medicine (tenecteplase) is safe for people having a severe stroke who did not improve after the first dose. It aims to help dissolve the clot better and improve recovery without causing harmful bleeding.

Houston, Texas
NCT06841978Not yet recruiting· Phase 3
Clot-busting treatment for a second stroke within 24 hours

This study tests whether a clot-busting medicine given through a vein can help people who have had a stroke in the last 3 months and are now having another stroke. The goal is to see if this treatment is safe and improves recovery.

NCT07047326Recruiting
Urokinase for acute ischemic stroke within 6 hours

This trial tests whether the clot-busting drug urokinase can help people who have had an ischemic stroke (a stroke caused by a blood clot). The goal is to dissolve the clot and improve recovery, as long as treatment starts within 6 hours of the first symptoms.

Beijing, Beijing Municipality

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.